Cipla

Aditya Birla Group forayed into the wires and cables market with an investment of ₹1,800 crore. The new business will operate through its cement arm UltraTech Cement, under the Ultravolt brand.

Drug major Cipla Ltd on Thursday said its wholly owned subsidiary, Invagen Pharmaceuticals Inc, has entered into a strategic partnership with Qilu Pharmaceutical for the licensing and supply of a biosimilar to the cancer drug Keytruda in the United States. The product, QL2107, is a biosimilar to pembrolizumab (Keytruda) and aims to improve access to advanced therapies for cancer patients while lowering treatment costs, Cipla said in a regulatory filing. Under the agreement, Qilu will be responsible for the development, regulatory registration, and supply of the product, while Cipla will leverage its commercial presence to market the asset in the US. "This partnership reflects Cipla's confidence in the long-term potential of biosimilars and supports our strategy to build a strong oncology-focused portfolio," said Achin Gupta, Managing Director and Global Chief Executive Officer, Cipla. Hanchang Zhang, General Manager of Qilu Pharmaceutical, said, "We are pleased to establish this ..

Stocks to watch today: HDFC Bank's shares will remain in focus after bank's MD & CEO, Sashidhar Jagdishan, decided not to seek reappointment.

State regulator cites alleged packaging, inventory and storage violations at Cipla's Pune C&F warehouse; company challenges order, says matter is sub judice

From generics to global leadership, India's pharmaceutical industry has transformed since 1991. Its next challenge is becoming a global hub for breakthrough drug innovation

Cipla reported a 39.2 per cent fall in net profit for the first quarter to ₹789.05 crore on a year-on-year basis. Revenue for the quarter was up at ₹7,119.28 crore

The drugmaker attributed the decline to a high base in North America, retained its FY27 Ebitda margin guidance and expects new product launches to support growth

Revenue from operations rose 2.3 per cent ‌to ₹7,119 crore, beating estimates of ₹7,073 crore

Total expenses rose 14.7 per cent to ₹6,248.25 crore, outpacing reported revenue growth; Cipla also changed the presentation of promotional spending in its accounts

Q1 results updates: Firms including Coromandel International, Mphasis, Chennai Petroleum Corporation, and Motilal Oswal Financial Services are also to release their April-June earnings today

Imported generics to remain tariff-free for two years; industry doubts US can build a cost-competitive manufacturing ecosystem within the transition period

Pharma stocks: RPG Life, Thyrocare, Hester Biosciences, Rubicon Research, IOL Chemicals, Emcure and Suven Life from the BSE Healthcare index rallied between 4% and 8% on Monday.

The expanding domestic market for semaglutide-based weight-loss drugs is expected to help cushion weaker US sales for Cipla and Dr Reddy's after the loss of Revlimid exclusivity

Here's why Nandish Shah technical research analyst of HDFC Securities recommends a 'Bull Spread' strategy on Cipla and United Spirits derivatives for the July series.

Homegrown pharma major Cipla Ltd on Tuesday announced the appointment of Shivam Puri as the CEO of its 'One India Business' with effect from July 1, 2026. Puri, currently Managing Director and CEO of Cipla Health Ltd, a wholly-owned subsidiary of the company, has over 23 years of leadership experience across both FMCG and healthcare sectors. He brings strong commercial acumen and consumer-centric expertise, Cipla said in a regulatory filing. He took over as MD and CEO of Cipla Health in 2019, and under his leadership, the company rapidly expanded its portfolio and strengthened its presence across key consumer categories, such as smoking cessation, pain care, cough and cold, skin care, hair care and nutrition, among others, Cipla said. Before joining Cipla Health in 2019, Puri held senior leadership roles at Hindustan Unilever, Jubilant FoodWorks and ITC Ltd, the filing said.

Filed 10 applications with USFDA in FY26 to build a pipeline of differentiated products for regulated markets

Boston-headquartered MedTherapy Biotech is expanding its India manufacturing footprint while preparing clinical trials for a lymphoma-focused CAR-T therapy with Cipla

Strong India and Africa growth partially offset weakness in North America as Cipla focuses on respiratory launches and regulatory filings

Going forward Cipla's management expects to pick up momentum in FY27 and aspires $1 billion revenue from the US itself.

Drugmaker cites lower contribution from key US products, higher R&D investments and rising operating costs as Q4 FY26 profit declines sharply